{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:15:41Z","timestamp":1769127341980,"version":"3.49.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2610,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis with Val30Met mutations. However, its efficacy in TTR amyloid cardiomyopathy is not fully elucidated. Herein, we report a 73-year-old Japanese man with a diagnosis of TTR amyloid cardiomyopathy with Val30Met mutation treated with tafamidis. To evaluate treatment response, cardiac magnetic resonance imaging was performed before and after 12 months of tafamidis treatment. Native T1, extracellular volume, and left ventricular mass showed no obvious worsening, and findings of other diagnostic studies also supported the efficacy of tafamidis to delay the progression of amyloid cardiomyopathy. Our case suggests that serial native T1 and extracellular volume may be novel non-invasive imaging methods to monitor the treatment response to TTR stabilizers in cardiac amyloidosis and also that tafamidis may be effective in suppressing cardiac progression in TTR amyloid cardiomyopathy with Val30Met mutation.<\/jats:p>","DOI":"10.1002\/ehf2.12382","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T04:36:01Z","timestamp":1543293361000},"page":"232-236","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Monitoring Treatment Response to Tafamidis by Serial Native T1 and Extracellular Volume in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1093","volume":"6","author":[{"given":"Yasuhiro","family":"Shintani","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hamatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takahama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Amaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Ohta-Ogo","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatsue","family":"Ishibashi-Ueda","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shimazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center , Kyoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneaki","family":"Yoshinaga","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine , Matsumoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Yazaki","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine , Matsumoto ,","place":["Japan"]},{"name":"Department of Biological Sciences for Intractable Neurological Diseases, Institute for Biomedical Sciences, Shinshu University , Matsumoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine , Matsumoto ,","place":["Japan"]},{"name":"Department of Biological Sciences for Intractable Neurological Diseases, Institute for Biomedical Sciences, Shinshu University , Matsumoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"2026012115102157600_ehf212382-bib-0001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"2026012115102157600_ehf212382-bib-0002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2016.01.046","article-title":"Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study","volume":"362","author":"Ando","year":"2016","journal-title":"J Neurol Sci"},{"key":"2026012115102157600_ehf212382-bib-0003","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012115102157600_ehf212382-bib-0004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.amjcard.2011.03.040","article-title":"Rate of progression of transthyretin amyloidosis","volume":"108","author":"Benson","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012115102157600_ehf212382-bib-0005","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.amjcard.2017.08.024","article-title":"Predictors of prognosis in light-chain amyloidosis and chronological changes in cardiac morphology and function","volume":"120","author":"Amano","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026012115102157600_ehf212382-bib-0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00392-016-1067-9","article-title":"Unusual case of ATTR amyloidosis with cardiac manifestation and situs inversus totalis","volume":"106","author":"Fritschka","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2026012115102157600_ehf212382-bib-0007","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"2026012115102157600_ehf212382-bib-0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"key":"2026012115102157600_ehf212382-bib-0009","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026012115102157600_ehf212382-bib-0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012115102157600_ehf212382-bib-0011","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115102157600_ehf212382-bib-0012","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","article-title":"Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy","volume":"287","author":"Koike","year":"2009","journal-title":"J Neurol Sci"},{"key":"2026012115102157600_ehf212382-bib-0013","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/jcpt.12145","article-title":"Recent progress in the understanding and treatment of transthyretin amyloidosis","volume":"39","author":"Sekijima","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2026012115102157600_ehf212382-bib-0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jjcc.2017.10.003","article-title":"Recent advances in diagnosis and treatment of cardiac amyloidosis","volume":"71","author":"Izumiya","year":"2018","journal-title":"J Cardiol"},{"key":"2026012115102157600_ehf212382-bib-0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000455089","article-title":"Tafamidis for the treatment of hereditary transthyretin amyloid cardiomyopathy: a case report","volume":"137","author":"Fujita","year":"2017","journal-title":"Cardiology"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/1\/232\/66135781\/eschf_6_1_232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/1\/232\/66135781\/eschf_6_1_232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:13:22Z","timestamp":1769026402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/1\/232\/8403637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,11,27]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12382","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"2018-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}